Attendance in person is not permitted
LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the "Notice"), which can be viewed and downloaded from www.autolus.com. The Notice states that the AGM is scheduled to be held at Autolus headquarters in White City at 1.00 pm BST (8.00 am EDT) on Thursday, June 18, 2020.
Given the coronavirus pandemic, the UK government passed into law certain compulsory measures prohibiting, amongst other things, public gatherings of more than two people (“Stay at Home Measures”). In order to ensure that our AGM may proceed on Thursday, June 18, 2020 in compliance with the Stay at Home Measures, arrangements have been made for a quorum of two shareholders only to be present at our AGM this year. On this basis, the Board has concluded that as long as the Stay at Home Measures remain in force, shareholders must not attend the AGM in person this year and, instead, should submit proxy votes as described in the Notice. In compliance with the Stay at Home Measures, it is expected that no members of the Board will attend the AGM in person.
Arrangements for the 2020 AGM
The AGM will be convened at the address set out in the Notice with the minimum required quorum of two shareholders present in order to conduct the business of the meeting. The results of the poll votes on the proposed resolutions will be announced, in the usual way, via a press release, as soon as practicable after the conclusion of the AGM. Given the meeting format changes, and the need to keep the people present to a minimum, no webcast will be provided.
It is as important as ever that shareholders cast their votes in respect of the business of the AGM. This year, if you want your vote to count, you must vote ahead of the meeting as it will not be possible to do so during the AGM. Any advance voting must be done by completing a proxy form, submitting proxy instructions electronically or casting your votes through the medium attributable to the way that you hold your shares. We strongly encourage you to vote as early as possible.
If appointing a proxy, shareholders are strongly encouraged to appoint the "Chair of the meeting" to ensure their appointed proxy is present and can vote on their behalf.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.
Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
+44 (0) 7818 430 877
Susan A. Noonan
S.A. Noonan Communications
Source: Autolus Therapeutics plc